Generic knowledge strategies in the U.S. pharmaceutical industry

Article Abstract:

A study examined generic knowledge strategies in the American pharmaceutical industry. This research focused on the knowledge practices of 21 drug companies between 1977 and 1991. The firms were grouped via cluster analysis according to such variables as balance between internal and external learning, preference for radical or incremental learning, learning speed, and breadth of knowledge base. Findings revealed four generic knowledge strategy groups: explorers, exploiters, loners and innovators. Firms in the innovator and explorer groups were found to demonstrate greater profitability than those in the exploiter and longer groups. Moreover, firms usually stayed in a single knowledge group across time.

Pharmaceutical Preparations, Research, Pharmaceutical industry, Drugs, Organizational effectiveness, Knowledge, Theory of, Epistemology

---

VDC: a cavity to fill

Article Abstract:

VDC acquired Procare, which supplies dental practices, in 1996. Procare has since been found to have accounting problems and interim results reported in Feb 1996 show a loss for Procare of 142,000 pounds sterling with sales of 6.5 million pounds. Meanwhile, VDC has acquired Firmadenta which supplies branded dental products. VDC saw a rise in operating profit for its core operation which is animal healthcare. VDC's profit is forecast at 1.7 million pounds sterling for 1997 and 2 million pounds for 1998 by Beeson Gregory.

Veterinary Supplies Whsle, Other Professional Equipment and Supplies Wholesalers, Medical and hospital equipment, Medical Supplies Whsle, Medical, Dental, and Hospital Equipment and Supplies Wholesalers, Professional equipment, not elsewhere classified, Medical supplies wholesalers, Veterinary supplies, Dental equipment and supplies industry, Dental equipment industry, VDC

---

Ceva regaining Galastop

Article Abstract:

Ceva Sante Animale (Libourne, France) will take over all distribution of Galastop, a prolactin inhibitor veterinary drug, throughout Europe by 2003, as contracts with its current distributors come to an end. The drug, available throughout the European Union, Switzerland and Norway, had total sales of Francs 22 million in 2000.

Europe, Veterinary Reproductive Regulators, Veterinary drugs, Ceva Sante Animale

Similar abstracts:

• Abstracts: An empirical analysis of sustained advantage in the U.S. pharmaceutical industry: impact of firm resources and capabilities

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.